Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.3.44 (
P-glycoprotein
)
13,344
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In the past decade major advances have been made towards understanding the mechanisms by which polytopic membrane proteins fold and assemble in cellular membranes. In eukaryotes, this process is mediated by a complex set of machinery in the
endoplasmic reticulum
(ER) that facilitates translocation of peptide loops across and integration of hydrophobic helices into the lipid bilayer. Studies evaluating the biogenesis of
P-glycoprotein
(
P-gp
) have been at the forefront of this rapidly expanding field. They have revealed a fascinating although sometimes confusing picture that has challenged our notions about general mechanisms of polytopic protein assembly and questioned specific predictions about the details and uniqueness of
P-gp
transmembrane topology. This review will attempt to summarize and consolidate our current knowledge of the sequence of events that gives rise to
P-gp
topology in the ER compartment and the implications of these events for polytopic protein biogenesis and function.
...
PMID:Molecular mechanism of P-glycoprotein assembly into cellular membranes. 1236 97
Photodynamic therapy has clinical indications in treatment of localized cancers and could be interesting for eradication of local recurrence of chemoresistant tumors. In the present study, the intracellular accumulation and distribution of chlorin e6 was investigated in MCF-7 and in
P-glycoprotein
overexpressing, doxorubicin resistant MCF-7/DXR cell lines. After 3-h incubation with chlorin e6 (1.7 micro mol.l(-1)), no significant difference in accumulation was observed between MCF-7 and MCF-7/DXR cells. Chlorin e6 cellular efflux did not differ in the two cell lines. The lack of influence of
P-glycoprotein
was confirmed since SDZ-PSC833 (PSC) had no influence in chlorin e6 accumulation and efflux in MCF-7/DXR cells. The subcellular distribution of chlorin e6 appeared different in MCF-7/DXR than in MCF-7 cells. Double staining colocalization fluorescence microscopy studies were performed to identify the subcellular localization sites for chlorin e6 using organelle probes for
endoplasmic reticulum
, Golgi apparatus, mitochondria and lysosomes. In MCF-7, chlorin e6 was distributed in all cytoplasmic organelles including
endoplasmic reticulum
and Golgi. In MCF-7/DXR, a diffuse cytoplasmic distribution was observed excepted for the
endoplasmic reticulum
and Golgi area in which less chlorin e6 was distributed. In MCF-7/DXR, PSC was found to restore the distribution of chlorin e6 in the
endoplasmic reticulum
and Golgi area while in MCF-7, no effect on the subcellular distribution of chlorin e6 was observed. Although the photodynamic activity of chlorin e6 (1.7 micro mol.l(-1), 650 nm, 8 mW.cm(-2)) was found to be lower in MCF-7/DXR than in MCF-7 cells, PSC was found to potentiate the photodynamic activity of chlorin e6 to similar extent in both cell lines. These results clearly demonstrate that PSC potentiates the photodynamic activity of Chlorin e6 independently of the expression of
P-glycoprotein
and further suggest that the photodynamic activity of chlorin e6 could be related to its intracellular distribution in the
endoplasmic reticulum
and the Golgi.
...
PMID:The multidrug resistance modulator SDZ-PSC 833 potentiates the photodynamic activity of chlorin e6 independently of P-glycoprotein in multidrug resistant human breast adenocarcinoma cells. 1263 62
In our present study, a
P-glycoprotein
-EGFP (P-gp-EGFP) fusion plasmid was constructed and functionally expressed in HeLa cells to investigate the intracellular localization and trafficking of
P-glycoprotein
(
P-gp
). Using immunocytochemistry and fluorescent confocal microscopy techniques, colocalization studies showed that after transfection,
P-gp
-EGFP was progressively transported from the
endoplasmic reticulum
(ER) to the Golgi and finally to the plasma membrane within 12-48 hr. The degree of intracellular accumulation of daunorubicin was related to the particular localization of
P-gp
-EGFP. Significant daunorubicin accumulation occurred in transfected cells when
P-gp
-EGFP was localized predominantly within the ER, and accumulation remained high when
P-gp
-EGFP was mainly localized in the Golgi. However, there was little or no intracellular accumulation of daunorubicin when
P-gp
-EGFP was localized predominantly on the plasma membrane. Blocking the intracellular trafficking of
P-gp
-EGFP with brefeldin A (BFA) and monensin resulted in inhibition of traffic of
P-gp
-EGFP and retention of
P-gp
-EGFP intracellularly. Intracellular accumulation of daunorubicin also increased in the presence of BFA or monensin. Our study shows that
P-gp
-EGFP can be used to define the dynamics of
P-gp
traffic in a transient expression system, and demonstrates that localization of
P-gp
on the plasma membrane is associated with the highest level of resistance to daunorubicin accumulation in cells. Modulation of intracellular localization of
P-gp
with agents designed to selectively modify its traffic may provide a new strategy for overcoming multidrug resistance in cancer cells.
...
PMID:Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: Implications in multidrug resistance in cancer. 1475 Jan 66
The most common mutation in cystic fibrosis (deletion of Phe-508 in the first nucleotide binding domain (DeltaF508)) in the cystic fibrosis transmembrane conductance regulator (CFTR) causes retention of the mutant protein in the
endoplasmic reticulum
. We previously showed that the DeltaF508 mutation causes the CFTR protein to be retained in the
endoplasmic reticulum
in an inactive and structurally altered state. Proper packing of the transmembrane (TM) segments is critical for function because the TM segments form the chloride channel. Here we tested whether the DeltaF508 mutation altered packing of the TM segments by disulfide cross-linking analysis between TM6 and TM12 in wild-type and DeltaF508 CFTRs. These TM segments were selected because TM6 appears to line the chloride channel, and cross-linking between these TM segments has been observed in the CFTR sister protein, the multidrug resistance
P-glycoprotein
. We first mapped potential contact points in wild-type CFTR by cysteine mutagenesis and thiol cross-linking analysis. Disulfide cross-linking was detected in CFTR mutants M348C(TM6)/T1142C(TM12), T351C(TM6)/T1142C(TM12), and W356C(TM6)/W1145C(TM12) in a wild-type background. The disulfide cross-linking occurs intramolecularly and was reducible by dithiothreitol. Introduction of the DeltaF508 mutation into these cysteine mutants, however, abolished cross-linking. The results suggest that the DeltaF508 mutation alters interactions between the TM domains. Therefore, a potential target to correct folding defects in the DeltaF508 mutant of CFTR is to identify compounds that promote correct folding of the TM domains.
...
PMID:The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. 1527 10
The proteasome is a multi-protein complex that degrades cellular proteins as well as foreign proteins destined for antigen presentation. The latter function involves the immunoproteasome, in which several proteasome subunits are exchanged for gamma-interferon-induced subunits. The transporter associated with antigen processing (TAP) transports proteasome-generated peptides across the membrane of the
endoplasmic reticulum
(ER) prior to presentation on the plasma membrane. We demonstrate interactions between the cytoplasmic domains of TAP subunits and subunits of both the proteasome and the immunoproteasome, suggesting direct targeting of antigenic peptides to the ER via a TAP-proteasome association. We also show interaction between one of the cytoplasmic domains of
P-glycoprotein
and a proteasome subunit, but not the corresponding immunoproteasome subunit, suggesting a possible role for
P-glycoprotein
in the transport of proteasome-derived peptides.
...
PMID:Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome. 1548 52
Misprocessed plasma membrane proteins of CFTR and
P-glycoprotein
(
P-gp
) are retained in the
endoplasmic reticulum
(ER) by molecular chaperones. Depletion of the calcium stores in the ER by the SERCA calcium pump inhibitors thapsigargin or curcumin inhibits these interactions and allows the protein to be trafficked to the plasma membrane [Nat. Med. 8 (2002) 485; Science 304 (2004) 600]. We tested this hypothesis by treating various cell lines expressing misprocessed mutants of CFTR or
P-gp
with thapsigargin or curcumin. Conversion of the immature core-glycosylated protein to mature product was detected by immunoblot analysis of whole cell extracts. Mature product was not detected in any of the misprocessed mutants. By contrast, all misprocessed
P-gp
mutants were rescued by the chemical chaperone/drug substrate cyclosporin A in a dose-dependent manner. These results show that thapsigargin or curcumin is not effective in rescuing misprocessed mutants of
P-gp
and CFTR.
...
PMID:Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein. 1553 Apr 32
Hepatic insulin resistance and lipoprotein overproduction are common features of the metabolic syndrome and insulin-resistant states. A fructose-fed, insulin-resistant hamster model was recently developed to investigate mechanisms linking the development of hepatic insulin resistance and overproduction of atherogenic lipoproteins. Here we report a systematic analysis of protein expression profiles in the
endoplasmic reticulum
(ER) fractions isolated from livers of fructose-fed hamsters with the intention of identifying new candidate proteins involved in hepatic complications of insulin resistance and lipoprotein dysregulation. We have profiled hepatic ER-associated proteins from chow-fed (control) and fructose-fed (insulin-resistant) hamsters using two-dimensional gel electrophoresis and mass spectrometry. A total of 26 large scale two-dimensional gels of hepatic ER were used to identify 34 differentially expressed hepatic ER protein spots observed to be at least 2-fold differentially expressed with fructose feeding and the onset of insulin resistance. Differentially expressed proteins were identified by matrix-assisted laser desorption ionization-quadrupole time of flight (MALDI-Q-TOF), MALDI-TOF-postsource decay, and database mining using ProteinProspector MS-fit and MS-tag or the PROWL ProFound search engine using a focused rodent or mammalian search. Hepatic ER proteins ER60, ERp46, ERp29, glutamate dehydrogenase, and TAP1 were shown to be more than 2-fold down-regulated, whereas alpha-glucosidase,
P-glycoprotein
, fibrinogen, protein disulfide isomerase, GRP94, and apolipoprotein E were all found to be up-regulated in the hepatic ER of the fructose-fed hamster. Seven isoforms of ER60 in the hepatic ER were all shown to be down-regulated at least 2-fold in hepatocytes from fructosefed/insulin-resistant hamsters. Implications of the differential expression of positively identified protein factors in the development of hepatic insulin resistance and lipoprotein abnormalities are discussed.
...
PMID:Proteomic profiling of hepatic endoplasmic reticulum-associated proteins in an animal model of insulin resistance and metabolic dyslipidemia. 1576 Aug 93
Cystic fibrosis (CF) is most commonly caused by deletion of Phe508 in the cystic fibrosis transmembrane conductance regulator protein (DeltaF508 CFTR). The misfolded DeltaF508 CFTR protein is retained in the
endoplasmic reticulum
(misprocessed mutant) and is rapidly degraded. Studies on misprocessed mutants of
P-glycoprotein
(
P-gp
), a sister protein of CFTR, however, have shown that specific substrates and modulators can act as specific chemical/pharmacological chaperones to rescue the protein. A major goal in CF research is the identification of compounds that can be used at low concentrations to rescue misprocessed CFTR mutants. Here, we show that a novel quinazoline derivative, 4-cyclohexyloxy-2-{1-[4-(4-methoxy-benzenesulfonyl)piperazin-1-yl]ethyl}quinazoline (CF(cor)-325), rescued DeltaF508 CFTR. Incubation of BHK cells stably expressing human DeltaF508 CFTR with 1-10 microM CF(cor)-325 resulted in maturation and delivery of a functional molecule to the cell surface as determined by the iodide efflux assay. The misprocessed CFTR mutants R258G, S945L, and H949Y were also rescued by CF(cor)-325 in either BHK or HEK 293 cells. CF(cor)-325 appeared to be specific for DeltaF508 CFTR because another quinazoline derivative, prazosin, did not rescue the misprocessed CFTR mutants. CF(cor)-325 could also rescue misprocessed mutants of
P-gp
. The compound was a
P-gp
inhibitor as it inhibited vinblastine-stimulated ATPase activity.
P-gp
-mediated vinblastine resistance was also reduced about 10-fold with 300 nM CF(cor)-325. These results show that CF(cor)-325 is a particularly important lead compound for treatment of CF because low concentrations can be used to rescue many misprocessed CFTR mutants.
...
PMID:Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. 1619 93
Transport of several xenobiotics including pharmacological agents into or out of the central nervous system (CNS) involves the expression of ATP-dependent, membrane-bound efflux transport proteins such as
P-glycoprotein
(
P-gp
) at the blood-brain barrier (BBB). Previous studies have documented gene and protein expression of
P-gp
in brain microvessel endothelial cells. However, the exact localization of
P-gp
, particularly at the abluminal side of the BBB, remains controversial. In the present study we examined the cellular/subcellular distribution of
P-gp
in situ in rat and human brain tissues using immunogold cytochemistry at the electron microscope level.
P-gp
localizes to both the luminal and abluminal membranes of capillary endothelial cells as well as to adjacent pericytes and astrocytes. Subcellularly,
P-gp
is distributed along the nuclear envelope, in caveolae, cytoplasmic vesicles, Golgi complex, and rough
endoplasmic reticulum
(RER). These results provide evidence for the expression of
P-gp
in human and rodent brain capillary along their plasma membranes as well as at sites of protein synthesis, glycosylation, and membrane trafficking. In addition, its presence at the luminal and abluminal poles of the BBB, including pericytes and astrocyte plasma membranes, suggests that this glycoprotein may regulate drug transport processes in the entire CNS BBB at both the cellular and subcellular level.
...
PMID:In situ localization of P-glycoprotein (ABCB1) in human and rat brain. 1680 29
P-glycoprotein
(Pgp), a plasma membrane (PM) glycoprotein, is responsible for the development of multidrug resistance. The mechanism by which Pgp is targeted to the PM is not defined. To identify proteins that influence Pgp trafficking, we utilized the yeast two-hybrid analysis procedure, which identified a new isoform of
endoplasmic reticulum
(ER)-bound Bap29, termed Bap29varP, as an interacting protein with the N-terminus of Pgp. The drug-resistant human breast cancer MCF-7 (MCF-7/Adr(R)) cells express both Bap29varP and approximately 170 kDa Pgp, which are however absent in the drug-sensitive MCF-7 cells. When Bap29varP was overexpressed in MCF-7/Adr(R) cells, Pgp was predominantly localized in the ER and intracellular vesicles, suggesting Bap29varP influences Pgp trafficking. When Pgp was expressed in MCF-7 cells, it was exclusively found in the ER with a molecular mass of approximately 160 kDa slightly smaller than that of the molecular mass of Pgp expressed in MCF-7/Adr(R) cells. On the other hand, when Pgp was expressed in Bap29varP-containing human colon adenocarcinoma HT-29 cells, it was localized at the PM. These findings together suggest that Bap29varP acts as an essential chaperone, influencing the processing and trafficking of Pgp to the cell surface.
...
PMID:Bap29varP, a variant of Bap29, influences the cell surface expression of the human P-glycoprotein. 1809 52
<< Previous
1
2
3
4
5
6
7
8
Next >>